Asia-Pacific Writing in the May edition of DIA’s Global Forum magazine, Toshiyoshi Tominaga of the Asia-Pacific Self-Medication Industry (APSMI) looks at the landscape for OTC medicines in the Asia-Pacific region today. Tominaga highlights how, against the backdrop of a drop in formal medical interventions due to COVID-19 infection fears, countries are more than…
Japan Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the world’s most innovative and technologically advanced countries – has lagged behind in terms of VC funding, especially in the life sciences and how this can be…
Australia In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA), discuss regulatory strategies and other initiatives designed to help nurture clinical research and product development in Australia post-pandemic. With…
MEA Mohamed Nasser, Amgen’s general manager for the vast Middle East & Africa (MEA) region, leverages his considerable experience managing teams across the region to highlight four skills (and one secret ingredient) that pharma country and regional managers in MEA need to succeed. The Middle East-Africa area (MEA) is one…
USA Writing in the May edition of DIA’s Global Forum magazine, Erica Lyons, Sarrit Kovacs, Matthew Kowalik, and Jessica Lee from the Division of Gastroenterology, Office of New Drugs, CDER at the US FDA look at how patient input is increasingly being utilised in new drug development, its importance in assessing…
Global The issue of COVID-19 vaccine access in developing nations has thrust intellectual property (IP) into global headlines. Against the backdrop of heated arguments both for and against an IP waiver for COVID-related products, the global pharma industry has launched a new initiative on IP, asserting its crucial importance to continued…
Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production. 2020 was defined by an increase in demand for dietary supplements because…
Switzerland Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across a vast array of areas including digital technology and cell and gene. He also discusses how Santen has leveraged its…
Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm. COVID has led…
Spain The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle drug delivery technologies; the agreement between Esteve and Kowa to license an acute pain product currently in Phase III; and the growth of the Spanish pharma market in February after falling 4…
Switzerland The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI) by 38 percent and NASDAQ Biotech by 46 per cent between 2015 and 2020. Key listings include Kuros Biosciences, Idorsia, Polyphor, ObsEva, and IGEA Pharma Made with Visme Infographic Maker To read more about the Swiss biotech investment…
UK Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of COVID-19 and Brexit seem set to muddy the waters of cross-border pharma trade for some time to come. Five…
See our Cookie Privacy Policy Here
